Paradigm Shift in Management of Unresectable Hepatocellular Carcinoma (uHCC) In Hong Kong, liver cancer is the fifth most common cancer (with 1,771 new cases of liver cancer reported in 2021) and the third most common cause of cancer-related deaths ...
Chronic Lymphocytic Leukaemia (CLL) is a lymphoproliferative disorder characterised by the expansion of monoclonal, mature CD5+ CD23+ B cells in the peripheral blood, secondary lymphoid tissues, and bone marrow 1 . The molecular heterogeneity of CLL...
Principles for Treatment Selection The newly established European guidelines advocate IMiD-based therapies as the induction therapy for patients with newly diagnosed multiple myeloma (NDMM), regardless of eligibility for autologous stem cell transpl...
The management of relapsed and refractory multiple myeloma (RRMM) continues to be challenging though new therapeutics for the disease have been emerging in recent decades. Essentially, while decreased survival was observed in each extra line of ther...
Currently Available Therapeutic Options for MM MM is currently one of the most prevalent haematological malignancies, which mainly affects individuals aged above 65 2 , a relatively vulnerable group of patients owing to comorbidities and immunosenes...
The Multitude of Activities of IMiDs Because of the established benefits, IMiDs are recommended as induction therapy for both transplant eligible and ineligible patients, in the post-transplant maintenance setting, and for relapsed/refractory diseas...
Background Information The patient of the current case was a 64-year-old male with documented ischemic heart disease and received 3 times of percutaneous coronary intervention (PCI), respectively in 2004, 2005 and 2013. In 2015, the patient complain...
Reduced Overall Survival in Refractory MM Although the application of the first IMiD, lenalidomide, had significantly increased median overall survival (OS) 2 , Prof. Leleu commented that the treatment success was hindered by the refractoriness of M...
Therapeutic Sequencing Strategy in Multiple Myeloma Date: 24 th June 2021 (Thursday) Time: 19:00 - 20:40 (GMT+8, HKT) Meeting format: Zoom meeting Address: Salon Room III, Hyatt Regency Hong Kong, 18 Hanoi Road, Tsim Sha Tsui, Kowloon The survival o...
Over the past 25 years, significant progress has been made in the treatment of multiple myeloma (MM) as reflected by the improved overall survival (OS). However, in relapsed and refractory MM (RRMM), median OS decreases with each extra line of thera...
T he Importance of Achieving Deepest Possible Response and Continuous Therapy While improving long-term survival for patients with MM is desirable, clinical data suggested that complete response (CR) to treatment is associated with survival outcomes...
Management of Relapsed and Refractory Multiple Myeloma Date: 25 February 2021 (Thursday) Time: 19:15 - 20:40 (GMT+8, HKT) Meeting format: Zoom meeting Webinar on Management of Relapsed and Refractory Multiple Myeloma Multiple myeloma (MM) is charact...
